SHP2 is a target of the immunosuppressant tautomycetin

Sijiu Liu, Zhihong Yu, Xiao Yu, Sheng Xiong Huang, Yinggang Luo, Li Wu, Weihua Shen, Zhenyun Yang, Lina Wang, Andrea M. Gunawan, Rebecca Chan, Ben Shen, Zhong-Yin Zhang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

SHP2 phosphatase is a positive transducer of growth factor and cytokine signaling. SHP2 is also a bona fide oncogene; gain-of-function SHP2 mutations leading to increased phosphatase activity cause Noonan syndrome, as well as multiple forms of leukemia and solid tumors. We report that tautomycetin (TTN), an immunosuppressor in organ transplantation, and its engineered analog TTN D-1 are potent SHP2 inhibitors. TTN and TTN D-1 block T cell receptor-mediated tyrosine phosphorylation and ERK activation and gain-of-function mutant SHP2-induced hematopoietic progenitor hyperproliferation and monocytic differentiation. Crystal structure of the SHP2TTN D-1 complex reveals that TTN D-1 occupies the SHP2 active site in a manner similar to that of a peptide substrate. Collectively, the data support the notion that SHP2 is a cellular target for TTN and provide a potential mechanism for the immunosuppressive activity of TTN. Moreover, the structure furnishes molecular insights upon which therapeutics targeting SHP2 can be developed on the basis of the TTN scaffold.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalChemistry and Biology
Volume18
Issue number1
DOIs
StatePublished - Jan 28 2011

Fingerprint

Immunosuppressive Agents
Non-Receptor Type 11 Protein Tyrosine Phosphatase
Noonan Syndrome
Transplantation (surgical)
Phosphorylation
tautomycetin
Organ Transplantation
T-Cell Antigen Receptor
Molecular Structure
Transducers
Oncogenes
Phosphoric Monoester Hydrolases
Scaffolds
Molecular structure
Tyrosine
Tumors
Catalytic Domain
Intercellular Signaling Peptides and Proteins
Leukemia
Crystal structure

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Molecular Biology
  • Clinical Biochemistry
  • Molecular Medicine
  • Pharmacology

Cite this

SHP2 is a target of the immunosuppressant tautomycetin. / Liu, Sijiu; Yu, Zhihong; Yu, Xiao; Huang, Sheng Xiong; Luo, Yinggang; Wu, Li; Shen, Weihua; Yang, Zhenyun; Wang, Lina; Gunawan, Andrea M.; Chan, Rebecca; Shen, Ben; Zhang, Zhong-Yin.

In: Chemistry and Biology, Vol. 18, No. 1, 28.01.2011, p. 101-110.

Research output: Contribution to journalArticle

Liu, S, Yu, Z, Yu, X, Huang, SX, Luo, Y, Wu, L, Shen, W, Yang, Z, Wang, L, Gunawan, AM, Chan, R, Shen, B & Zhang, Z-Y 2011, 'SHP2 is a target of the immunosuppressant tautomycetin', Chemistry and Biology, vol. 18, no. 1, pp. 101-110. https://doi.org/10.1016/j.chembiol.2010.10.015
Liu, Sijiu ; Yu, Zhihong ; Yu, Xiao ; Huang, Sheng Xiong ; Luo, Yinggang ; Wu, Li ; Shen, Weihua ; Yang, Zhenyun ; Wang, Lina ; Gunawan, Andrea M. ; Chan, Rebecca ; Shen, Ben ; Zhang, Zhong-Yin. / SHP2 is a target of the immunosuppressant tautomycetin. In: Chemistry and Biology. 2011 ; Vol. 18, No. 1. pp. 101-110.
@article{06fcc9bc5e774d42a1adf25c29795d96,
title = "SHP2 is a target of the immunosuppressant tautomycetin",
abstract = "SHP2 phosphatase is a positive transducer of growth factor and cytokine signaling. SHP2 is also a bona fide oncogene; gain-of-function SHP2 mutations leading to increased phosphatase activity cause Noonan syndrome, as well as multiple forms of leukemia and solid tumors. We report that tautomycetin (TTN), an immunosuppressor in organ transplantation, and its engineered analog TTN D-1 are potent SHP2 inhibitors. TTN and TTN D-1 block T cell receptor-mediated tyrosine phosphorylation and ERK activation and gain-of-function mutant SHP2-induced hematopoietic progenitor hyperproliferation and monocytic differentiation. Crystal structure of the SHP2TTN D-1 complex reveals that TTN D-1 occupies the SHP2 active site in a manner similar to that of a peptide substrate. Collectively, the data support the notion that SHP2 is a cellular target for TTN and provide a potential mechanism for the immunosuppressive activity of TTN. Moreover, the structure furnishes molecular insights upon which therapeutics targeting SHP2 can be developed on the basis of the TTN scaffold.",
author = "Sijiu Liu and Zhihong Yu and Xiao Yu and Huang, {Sheng Xiong} and Yinggang Luo and Li Wu and Weihua Shen and Zhenyun Yang and Lina Wang and Gunawan, {Andrea M.} and Rebecca Chan and Ben Shen and Zhong-Yin Zhang",
year = "2011",
month = "1",
day = "28",
doi = "10.1016/j.chembiol.2010.10.015",
language = "English",
volume = "18",
pages = "101--110",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - SHP2 is a target of the immunosuppressant tautomycetin

AU - Liu, Sijiu

AU - Yu, Zhihong

AU - Yu, Xiao

AU - Huang, Sheng Xiong

AU - Luo, Yinggang

AU - Wu, Li

AU - Shen, Weihua

AU - Yang, Zhenyun

AU - Wang, Lina

AU - Gunawan, Andrea M.

AU - Chan, Rebecca

AU - Shen, Ben

AU - Zhang, Zhong-Yin

PY - 2011/1/28

Y1 - 2011/1/28

N2 - SHP2 phosphatase is a positive transducer of growth factor and cytokine signaling. SHP2 is also a bona fide oncogene; gain-of-function SHP2 mutations leading to increased phosphatase activity cause Noonan syndrome, as well as multiple forms of leukemia and solid tumors. We report that tautomycetin (TTN), an immunosuppressor in organ transplantation, and its engineered analog TTN D-1 are potent SHP2 inhibitors. TTN and TTN D-1 block T cell receptor-mediated tyrosine phosphorylation and ERK activation and gain-of-function mutant SHP2-induced hematopoietic progenitor hyperproliferation and monocytic differentiation. Crystal structure of the SHP2TTN D-1 complex reveals that TTN D-1 occupies the SHP2 active site in a manner similar to that of a peptide substrate. Collectively, the data support the notion that SHP2 is a cellular target for TTN and provide a potential mechanism for the immunosuppressive activity of TTN. Moreover, the structure furnishes molecular insights upon which therapeutics targeting SHP2 can be developed on the basis of the TTN scaffold.

AB - SHP2 phosphatase is a positive transducer of growth factor and cytokine signaling. SHP2 is also a bona fide oncogene; gain-of-function SHP2 mutations leading to increased phosphatase activity cause Noonan syndrome, as well as multiple forms of leukemia and solid tumors. We report that tautomycetin (TTN), an immunosuppressor in organ transplantation, and its engineered analog TTN D-1 are potent SHP2 inhibitors. TTN and TTN D-1 block T cell receptor-mediated tyrosine phosphorylation and ERK activation and gain-of-function mutant SHP2-induced hematopoietic progenitor hyperproliferation and monocytic differentiation. Crystal structure of the SHP2TTN D-1 complex reveals that TTN D-1 occupies the SHP2 active site in a manner similar to that of a peptide substrate. Collectively, the data support the notion that SHP2 is a cellular target for TTN and provide a potential mechanism for the immunosuppressive activity of TTN. Moreover, the structure furnishes molecular insights upon which therapeutics targeting SHP2 can be developed on the basis of the TTN scaffold.

UR - http://www.scopus.com/inward/record.url?scp=79251557809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251557809&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2010.10.015

DO - 10.1016/j.chembiol.2010.10.015

M3 - Article

VL - 18

SP - 101

EP - 110

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 1

ER -